These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 23360224)

  • 1. Gene-guided gefitinib switch maintenance therapy for patients with advanced EGFR mutation-positive non-small cell lung cancer: an economic analysis.
    Zhu J; Li T; Wang X; Ye M; Cai J; Xu Y; Wu B
    BMC Cancer; 2013 Jan; 13():39. PubMed ID: 23360224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China.
    Lu S; Ye M; Ding L; Tan F; Fu J; Wu B
    Oncotarget; 2017 Feb; 8(6):9996-10006. PubMed ID: 28036283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of first-line treatments for advanced epidermal growth factor receptor-mutant non-small cell lung cancer patients.
    Li WQ; Li LY; Chai J; Cui JW
    Cancer Med; 2021 Mar; 10(6):1964-1974. PubMed ID: 33626238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.
    Ting J; Tien Ho P; Xiang P; Sugay A; Abdel-Sattar M; Wilson L
    Value Health; 2015 Sep; 18(6):774-82. PubMed ID: 26409604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong - A cost-effectiveness analysis.
    You JHS; Cho WCS; Ming WK; Li YC; Kwan CK; Au KH; Au JS
    PLoS One; 2021; 16(3):e0247860. PubMed ID: 33647045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of Osimertinib as First-line Treatment and Sequential Therapy for EGFR Mutation-positive Non-small Cell Lung Cancer in China.
    Cai H; Zhang L; Li N; Chen S; Zheng B; Yang J; Weng L; Liu MB
    Clin Ther; 2019 Feb; 41(2):280-290. PubMed ID: 30639208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of EGFR mutation testing and gefitinib as first-line therapy for non-small cell lung cancer.
    Narita Y; Matsushima Y; Shiroiwa T; Chiba K; Nakanishi Y; Kurokawa T; Urushihara H
    Lung Cancer; 2015 Oct; 90(1):71-7. PubMed ID: 26259876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NICE guidance on erlotinib for first-line treatment of EGFR-TK mutation-positive advanced or metastatic non-small-cell lung cancer.
    Dillon B; Naidoo B; Knight H; Clark P
    Lancet Oncol; 2012 Aug; 13(8):764-5. PubMed ID: 23024988
    [No Abstract]   [Full Text] [Related]  

  • 9. Economic outcomes of maintenance gefitinib for locally advanced/metastatic non-small-cell lung cancer with unknown EGFR mutations: a semi-Markov model analysis.
    Zeng X; Li J; Peng L; Wang Y; Tan C; Chen G; Wan X; Lu Q; Yi L
    PLoS One; 2014; 9(2):e88881. PubMed ID: 24586426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.
    Wu B; Chen H; Shen J; Ye M
    Clin Ther; 2011 Oct; 33(10):1446-55. PubMed ID: 21992806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China.
    Gu X; Zhang Q; Chu YB; Zhao YY; Zhang YJ; Kuo D; Su B; Wu B
    Lung Cancer; 2019 Jan; 127():84-89. PubMed ID: 30642557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of adjuvant icotinib versus chemotherapy for patients with stage II-IIIA EGFR-mutated non-small cell lung cancer in China.
    Mu L; Liu F; Fang Y; He M; Yang M
    BMJ Open; 2024 Aug; 14(8):e081270. PubMed ID: 39179275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic Evaluation of Companion Diagnostic Testing for EGFR Mutations and First-Line Targeted Therapy in Advanced Non-Small Cell Lung Cancer Patients in South Korea.
    Lim EA; Lee H; Bae E; Lim J; Shin YK; Choi SE
    PLoS One; 2016; 11(8):e0160155. PubMed ID: 27483001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Budget Impact Analysis of Afatinib for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 19 Deletions or Exon 21 Substitution Mutations in a U.S. Health Plan.
    Graham J; Earnshaw S; Burslem K; Lim J
    J Manag Care Spec Pharm; 2018 Jun; 24(6):544-553. PubMed ID: 29799327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of policy options on first-line treatments for advanced, non-small cell lung cancer in Thailand.
    Limwattananon C; Limwattananon S; Waleekhachonloet O; Rattanachotphanit T
    Lung Cancer; 2018 Jun; 120():91-97. PubMed ID: 29748023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-utility of afatinib and gefitinib as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer.
    Wang H; Zeng C; Li X; Wang Y; Li X; Ge W
    Future Oncol; 2019 Jan; 15(2):181-191. PubMed ID: 30320506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of Osimertinib as a Second-line Treatment in Patients With EGFR-mutated Advanced Non-Small Cell Lung Cancer in China.
    Guan H; Liu G; Xie F; Sheng Y; Shi L
    Clin Ther; 2019 Nov; 41(11):2308-2320.e11. PubMed ID: 31607559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of osimertinib for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small cell lung cancer in Singapore.
    Aziz MIA; Foo WYX; Toh CK; Lim WT; Ng K
    J Med Econ; 2020 Nov; 23(11):1330-1339. PubMed ID: 32886557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of osimertinib in the UK for advanced EGFR-T790M non-small cell lung cancer.
    Bertranou E; Bodnar C; Dansk V; Greystoke A; Large S; Dyer M
    J Med Econ; 2018 Feb; 21(2):113-121. PubMed ID: 28880737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer.
    Carlson JJ; Garrison LP; Ramsey SD; Veenstra DL
    Value Health; 2009; 12(1):20-7. PubMed ID: 18647257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.